LP
OMED

LMR Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

LMR Partners’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60,347
Closed -$201K – 689
2017
Q2 		$201K Buy
+60,347
New +$250K 0.01% 524

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

LMR Partners's OMED Position: Q3 2017 in Review

LMR Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 60,347 shares — an estimated $201K sold.

LMR Partners first reported a position in OMED in Q2 2017 and held it in 1 quarter. The position peaked at $201K in Q2 2017. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

  • LMR Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • LMR Partners sold 60,347 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $201K.
  • LMR Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • LMR Partners's OncoMed Pharmaceuticals, Inc. position peaked at $201K in Q2 2017.
  • 58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.